Prognosis
Synthetic Bio Pioneer Ginkgo Raises $290 Million in New Funding
Boston-based biotech startup now has valuation of $4 billion
An automated inoculator machine is seen at the Ginkgo Bioworks Inc. facility in Boston.
Photographer: Scott Eisen/BloombergThis article is for subscribers only.
Ginkgo Bioworks Inc. raised $290 million in new funding, giving a boost to a startup that designs organisms to do everything from re-create the scent of an extinct Hawaiian hibiscus to treat liver disorders in humans.
The latest investment brings the Boston-based biotech’s total valuation to $4 billion, according to a person familiar with the company’s finances who wasn’t authorized to discuss them publicly.